生物仿真多多巴胺纳米系统的炎症级联指导疗法,用于长期管理缺血性中风
Yuyi Zheng1, Xiaojie Chen1, Qi Zhang1
1Zhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences and School of Basic Medical Sciences, The Fifth Affiliated Hospital (Huzhou Central Hospital), Zhejiang Chinese Medical University, Hangzhou, China.
Theranostics
|December 2, 2025
概括
一个新的仿生纳米系统 (MPP-B@MM) 通过向炎症和按需释放神经营养因子,提供长期中风恢复,在反损伤后改善大脑功能.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 神经科学是一个神经科学.
背景情况:
- 对中风的再输液疗法会导致由于持续的脑炎症造成的二次损伤.
- 需要有效的长期管理策略来应对再输血后缺血性中风的进展.
- 开发有针对性的疗法以减轻二次脑损伤至关重要.
研究的目的:
- 使用仿生多多巴胺纳米系统 (MPP-B@MM) 设计和评估一种炎症级联定向疗法.
- 评估纳米系统穿越血脑屏障并提供神经保护的能力.
- 研究纳米系统在缺血性中风中的长期治疗疗效和分子机制.
主要方法:
- 合成和MPP-B@MM纳米系统的特征.
- 细胞吸收的体外评估,血脑屏障的穿越,以及抗亡效应.
- 使用中脑动脉封闭模型进行体内评估,包括行为测试,免疫组织化学和mRNA测序.
主要成果:
- MPP-B@MM证明了细胞吸收的增强和血脑屏障的透.
- 该纳米系统在体外显著减少了线粒体损伤和保护神经元.
- 在体内研究证实了优越的长期治疗效果,Homx1被确定为化反应药物释放的关键标.
结论:
- 量身定制的纳米系统提供了急性神经保护和按需的治疗释放.
- 它在空间时间上增加了神经营养因子的表达,促进了缺血性中风后的大脑恢复.
- 这种方法为管理缺血性中风的长期后果提供了一个有希望的策略.
相关概念视频
Mitral Regurgitation III: Medical Management
686
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
686
Myocarditis III: Medical Management
343
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
343
Heart Failure V: Medical Management
626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
Heart Failure VI: Adjunct Therapies
632
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632
Cardiomyopathy II: Dilated Cardiomyopathy
790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790


